Gilotrif Approval Gives Boehringer Milestone, But Can It Compete With Tarceva?

FDA approval of its first oncology drug is a victory for Boehringer Ingelheim. Now comes another challenge – a commercial battle with Roche’s Tarceva, which is firmly established across lines of therapy for EGFR-positive lung cancer patients.